198 related articles for article (PubMed ID: 21245949)
1. Effects of rat anti-VEGF antibody in a rat model of corneal graft rejection by topical and subconjunctival routes.
Rocher N; Behar-Cohen F; Pournaras JA; Naud MC; Jeanny JC; Jonet L; Bourges JL
Mol Vis; 2011 Jan; 17():104-12. PubMed ID: 21245949
[TBL] [Abstract][Full Text] [Related]
2. Effect of a topically applied neutralizing antibody against vascular endothelial growth factor on corneal allograft rejection of rat.
Yatoh S; Kawakami Y; Imai M; Kozawa T; Segawa T; Suzuki H; Yamashita K; Okuda Y
Transplantation; 1998 Dec; 66(11):1519-24. PubMed ID: 9869094
[TBL] [Abstract][Full Text] [Related]
3. Novel micelle carriers for cyclosporin A topical ocular delivery: in vivo cornea penetration, ocular distribution and efficacy studies.
Di Tommaso C; Bourges JL; Valamanesh F; Trubitsyn G; Torriglia A; Jeanny JC; Behar-Cohen F; Gurny R; Möller M
Eur J Pharm Biopharm; 2012 Jun; 81(2):257-64. PubMed ID: 22445900
[TBL] [Abstract][Full Text] [Related]
4. Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival.
Dastjerdi MH; Saban DR; Okanobo A; Nallasamy N; Sadrai Z; Chauhan SK; Hajrasouliha AR; Dana R
Invest Ophthalmol Vis Sci; 2010 May; 51(5):2411-7. PubMed ID: 19892863
[TBL] [Abstract][Full Text] [Related]
5. Effects of subconjunctival ranibizumab in a presensitized rat model of corneal graft.
Cho KJ; Choi JS; Choi MY; Joo CK
Exp Eye Res; 2013 Feb; 107():74-9. PubMed ID: 23220731
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a topical cyclosporine A prodrug on corneal graft rejection in rats.
Bourges JL; Lallemand F; Agla E; Besseghir K; Dumont JM; BenEzra D; Gurny R; Behar-Cohen F
Mol Vis; 2006 Dec; 12():1461-6. PubMed ID: 17167400
[TBL] [Abstract][Full Text] [Related]
7. FK-506 delays corneal graft rejection in a model of corneal xenotransplantation.
Benelli U; Lepri A; Del Tacca M; Nardi M
J Ocul Pharmacol Ther; 1996; 12(4):425-31. PubMed ID: 8951679
[TBL] [Abstract][Full Text] [Related]
8. An Anti-VEGF-B Antibody Fragment Induces Regression of Pre-Existing Blood Vessels in the Rat Cornea.
Irani YD; Scotney PD; Klebe S; Mortimer LA; Nash AD; Williams KA
Invest Ophthalmol Vis Sci; 2017 Jul; 58(9):3404-3413. PubMed ID: 28692735
[TBL] [Abstract][Full Text] [Related]
9. [Ursolic acid inhibits corneal graft rejection following orthotopic allograft transplantation in rats].
Wang B; Wu J; Ma M; Li PP; Yu J
Nan Fang Yi Ke Da Xue Xue Bao; 2015 Apr; 35(4):530-5. PubMed ID: 25907938
[TBL] [Abstract][Full Text] [Related]
10. The Blockade of Vascular Endothelial Growth Factor C Effectively Inhibits Corneal Lymphangiogenesis and Promotes Allograft Survival.
Yan H; Yuan J; Peng R; Wang T; Deng J; Li W; Ling S
J Ocul Pharmacol Ther; 2015 Nov; 31(9):546-54. PubMed ID: 26172526
[TBL] [Abstract][Full Text] [Related]
11. Safety profile of topical VEGF neutralization at the cornea.
Bock F; Onderka J; Rummelt C; Dietrich T; Bachmann B; Kruse FE; Schlötzer-Schrehardt U; Cursiefen C
Invest Ophthalmol Vis Sci; 2009 May; 50(5):2095-102. PubMed ID: 19151400
[TBL] [Abstract][Full Text] [Related]
12. Corneal angiogenesis based on different protocols of alkaline cauterization in murine models.
Claros-Chacaltana FDY; Kobashigawa KK; Padua IRM; Valdetaro GP; Aldrovani M; Laus JL
Acta Cir Bras; 2017 Aug; 32(8):607-616. PubMed ID: 28902936
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of mouse alkali burn induced-corneal neovascularization by recombinant adenovirus encoding human vasohibin-1.
Zhou SY; Xie ZL; Xiao O; Yang XR; Heng BC; Sato Y
Mol Vis; 2010 Jul; 16():1389-98. PubMed ID: 20680097
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the effects of subconjunctival and topical anti-VEGF therapy (bevacizumab) on experimental corneal neovascularization.
Ozdemir O; Altintas O; Altintas L; Ozkan B; Akdag C; Yüksel N
Arq Bras Oftalmol; 2014 Aug; 77(4):209-13. PubMed ID: 25410169
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of a phosphorodiamidate morpholino oligomer antisense compound in the inhibition of corneal transplant rejection in a rat cornea transplant model.
Hosseini A; Lattanzio FA; Samudre SS; DiSandro G; Sheppard JD; Williams PB
J Ocul Pharmacol Ther; 2012 Apr; 28(2):194-201. PubMed ID: 22149555
[TBL] [Abstract][Full Text] [Related]
16. Topical and subconjunctival ranibizumab (lucentis) for corneal neovascularization in experimental rat model.
Türkcü FM; Cinar Y; Türkcü G; Sahin A; Cingü AK; Yüksel H; Sahin M; Yıldırım A; Caça I
Cutan Ocul Toxicol; 2014 Jun; 33(2):138-44. PubMed ID: 23859535
[TBL] [Abstract][Full Text] [Related]
17. Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization.
Al-Debasi T; Al-Bekairy A; Al-Katheri A; Al Harbi S; Mansour M
Saudi J Ophthalmol; 2017; 31(2):99-105. PubMed ID: 28559722
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor in a recipient cornea acts as a prognostic factor for corneal graft reaction development.
Sekelj S; Dekaris I; Balog T; Mahovne I; Krstonijevic EK; Janjetovic Z; Arar ZV; Aric I
Curr Eye Res; 2015 Apr; 40(4):407-14. PubMed ID: 24912114
[TBL] [Abstract][Full Text] [Related]
19. VEGF-trap aflibercept significantly improves long-term graft survival in high-risk corneal transplantation.
Dohlman TH; Omoto M; Hua J; Stevenson W; Lee SM; Chauhan SK; Dana R
Transplantation; 2015 Apr; 99(4):678-86. PubMed ID: 25606789
[TBL] [Abstract][Full Text] [Related]
20. Anti-VEGF Treatment in Corneal Diseases.
Giannaccare G; Pellegrini M; Bovone C; Spena R; Senni C; Scorcia V; Busin M
Curr Drug Targets; 2020; 21(12):1159-1180. PubMed ID: 32189591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
